Healthcare
Provectus Biopharmaceuticals, Inc.(PVCT)
Live Price
Offline$0.0617
-0.48% today
1Y Change
-20.90%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $20.00M
- Revenue Growth
- -45.5%
- EPS Growth
- -14.2%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Provectus Biopharmaceuticals, Inc. (PVCT) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.06 and down 20.9% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -45.5%, EPS growth of -14.2%, a dividend yield of 0.0%. What stands out right now is revenue -45.5%, EPS -14.2%, free cash flow -1.3% with operating margin -1514.5% and ROIC 153.1%. Valuation already assumes a fairly strong business story at price/sales 71.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PVCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-45.5% vs +7.6% peer median
Operating Margin
Below sector median
-1514.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -45.5% and EPS is at -14.2%, with operating margin around -1514.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -1.4% | -5.7% | -12.9% |
2026 Mar 25, 2026 | โ | -9.4% | -9.4% | +0.0% |
2025 Nov 13, 2025 | โ | +0.0% | +6.2% | -1.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PVCT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PVCT Max Drawdown
-60.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PVCT and SPY.
Company Overview
Provectus Biopharmaceuticals, Inc.
Other OTC
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
- Leadership
- Edward V. Pershing
- IPO Date
- Jan 15, 1997
- Employees
- 6
- Street Address
- 10025 Investment Drive
- Mailing
- Knoxville, TN, 37932
- Region
- Knoxville, TN, US
- Reporting Currency
- USD
- Investor Line
- 866 594 5999
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 71.3
- Price/Book
- โ
Growth
- Revenue
- -45.5%
- EPS
- -14.2%
- Free Cash Flow
- -1.3%
Profitability
- Gross Margin
- -13.7%
- Operating Margin
- -1514.5%
- Net Margin
- -1627.0%
- ROE
- 93.3%
- ROIC
- 153.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.